Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Jul;54(3):983-95.
doi: 10.1007/s12033-013-9655-7.

A comparative structural and bioanalytical study of IVIG clinical lots

Affiliations
Comparative Study

A comparative structural and bioanalytical study of IVIG clinical lots

Annamaria Sandomenico et al. Mol Biotechnol. 2013 Jul.

Abstract

Intravenous immunoglobulin are important bio-therapeutics used in the replacement therapy for primary and secondary immunodeficiencies, chronic inflammatory disorders and several autoimmune haematologic disorders. Currently, a number of immunoglobulin intravenous (IVIG) products have been approved by the Food and Drug Administration (FDA) and are available commercially. It is known that small differences in the manufacturing processes as well as in the formulations may affect their clinical efficacy and tolerability. Therefore, given the complexity of the multi-step process required for the isolation of IVIG from human plasma, it is necessary to ensure a rigorous quality control of final products. We show here that a set of different bioanalytical techniques can be conveniently used to comparatively characterize, at a quantitative and qualitative level, different lots of IVIG preparations and to unveil randomly occurring impurities which can also affect the overall product stability. We have used circular dichroism, surface plasmon resonance and two-dimensional electrophoresis (2DE), and have demonstrated that this combination of bioanalytical approaches is very useful to improve the quality control of antibodies and to monitor the reliability of the IVIG manufacturing process.

PubMed Disclaimer

References

    1. Expert Rev Clin Immunol. 2010 May;6(3):425-34 - PubMed
    1. Biophys J. 2000 Jan;78(1):394-404 - PubMed
    1. Am J Manag Care. 2012 Jun;18(4 Suppl):S67-78 - PubMed
    1. Anal Biochem. 1991 Nov 1;198(2):268-77 - PubMed
    1. Biopolymers. 2008 May;89(5):392-400 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources